Bernie Sanders calls vote to subpoena Novo Nordisk U.S. head over Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders has called a vote to subpoena the chief of Novo Nordisk’s U.S. division over the company’s pricing of the popular diabetes drug Ozempic and the obesity drug Wegovy, his office announced Tuesday.
The vote is scheduled for June 18. Sanders (I-Vt.) is seeking the appearance of Novo’s Doug Langa at a hearing next month. Sanders launched an investigation into Novo Nordisk’s pricing practices in April, and, he said that the committee “reached out time and time again” to schedule Novo Nordisk’s voluntary appearance at a hearing to no avail.
